X4 Pharmaceuticals (NASDAQ:XFOR) versus Annovis Bio (NYSE:ANVS) Head-To-Head Contrast

X4 Pharmaceuticals (NASDAQ:XFOR) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation.

Insider & Institutional Ownership

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

X4 Pharmaceuticals has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.

Profitability

This table compares X4 Pharmaceuticals and Annovis Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%
Annovis Bio	N/A	-318.08%	-215.47%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for X4 Pharmaceuticals and Annovis Bio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1	1	3	0	2.40
Annovis Bio	1	1	2	0	2.25

X4 Pharmaceuticals currently has a consensus target price of $8.50, indicating a potential upside of 110.71%. Annovis Bio has a consensus target price of $13.50, indicating a potential upside of 569.98%. Given Annovis Bio’s higher possible upside, analysts plainly believe Annovis Bio is more favorable than X4 Pharmaceuticals.

Valuation & Earnings

This table compares X4 Pharmaceuticals and Annovis Bio”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$9.01 million	42.21	-$79.20 million	($4.54)	-0.89
Annovis Bio	N/A	N/A	-$28.85 million	($1.71)	-1.18

Annovis Bio has lower revenue, but higher earnings than X4 Pharmaceuticals. Annovis Bio is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

X4 Pharmaceuticals beats Annovis Bio on 7 of the 13 factors compared between the two stocks.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

About Annovis Bio

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.